Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Positioning Aflibercept To Compete With Genentech’s Avastin In Certain Settings

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to file VEGF Trap for its first indication, ovarian cancer, in 2008, followed by second-line lung cancer and second-line colorectal cancer.

You may also be interested in...



Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC

Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.

Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC

Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.

Sunesis: Top-Line Phase II Data Positive In Ovarian Cancer

Early results generate interest from would-be partners, company tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS066612

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel